Roche (OTCMKTS:RHHBY) Upgraded by Zacks Research to Hold Rating

Key Points

• Zacks Research upgraded Roche from “strong sell” to “hold,” while MarketBeat’s analyst consensus remains “Hold” with a $60.00 target price.
• Analyst sentiment is mixed: HSBC downgraded Roche to “hold,” while Morgan Stanley upgraded it to “overweight” with a $63.00 target; five analysts rate it a Buy and six rate it a Hold.
• Roche shares opened at $58.47, up 1.7%, near the company’s 52-week high of $60.85 and above its 50- and 200-day moving averages.

Roche (OTCMKTS:RHHBY - Get Free Report) was upgraded by Zacks Research from a "strong sell" rating to a "hold" rating in a report released on Monday,Zacks.com reports.

A number of other research analysts have also commented on the company. HSBC lowered Roche from a "buy" rating to a "hold" rating in a research report on Monday, July 6th. Morgan Stanley upgraded Roche from an "equal weight" rating to an "overweight" rating and set a $63.00 target price for the company in a research report on Friday, August 7th. Five equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, Roche has a consensus rating of "Hold" and a consensus target price of $60.00.

Roche Trading Up 1.7%

Shares of Roche stock opened at $58.47 on Monday. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.38 and a quick ratio of 1.12. The firm has a 50 day simple moving average of $53.58 and a 200 day simple moving average of $52.95. Roche has a fifty-two week low of $39.50 and a fifty-two week high of $60.85.

Hedge Funds Weigh In On Roche

Large investors have recently bought and sold shares of the business. McIlrath & Eck LLC bought a new position in Roche in the first quarter valued at approximately $39,000. Oakworth Capital Inc. lifted its stake in shares of Roche by 20.8% in the 4th quarter. Oakworth Capital Inc. now owns 1,658 shares of the company's stock valued at $86,000 after purchasing an additional 285 shares during the period. Atlas Capital Advisors Inc. acquired a new position in shares of Roche in the 4th quarter valued at $192,000. Renasant Bank bought a new position in shares of Roche in the 2nd quarter worth $210,000. Finally, Pinnacle Wealth Management Advisory Group LLC acquired a new stake in shares of Roche during the first quarter worth $208,000.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY OTCMKTS: RHHBY.

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source